8-K: STAAR Surgical Reports Mixed Q1 Results, EVO ICL Sales Growth Continues

STAAR Surgical reported a 5% increase in net sales for Q1 2024, driven by a 9% rise in ICL sales, but experienced a net loss compared to the previous year's profit.

Summary

• STAAR Surgical's net sales for the first quarter of 2024 reached $77.4 million, a 5% increase compared to $73.5 million in the same period last year.
• ICL sales grew by 9%, contributing $6.5 million to the overall sales increase, while unit sales increased by 2%.
• Cataract IOL and other product sales decreased by $2.7 million due to the company exiting the cataract IOL business in 2023.
• The gross profit margin was 78.9%, slightly up from 78.3% in the prior year quarter.
• Operating expenses increased to $63.3 million from $54.8 million year-over-year, driven by higher general and administrative, research and development, and selling and marketing costs.
• The company reported a net loss of $3.3 million, or $0.07 per share, compared to a net income of $2.7 million, or $0.05 per share, in the first quarter of 2023.
• Adjusted EBITDA was $5.3 million, or $0.11 per share, down from $10.0 million, or $0.20 per share, in the prior year quarter.
• Cash, cash equivalents, and investments available for sale totaled $252.1 million as of March 29, 2024.
• The company reiterated its fiscal year 2024 net sales outlook of $335 million to $340 million and increased its adjusted EBITDA outlook to approximately $39 million, or $0.75 per diluted share.

Sentiment

Score: 6

Explanation: The sentiment is mixed. While there is positive growth in ICL sales and strategic agreements, the company reported a net loss and a decrease in adjusted EBITDA, which tempers the overall positive outlook.

Positives

• ICL sales continue to grow, demonstrating strong market adoption.
• The company is seeing strong growth in the U.S. market with record quarterly sales.
• The EMEA region is performing well, exceeding expectations.
• The company has a strong cash position with $252.1 million in cash, cash equivalents, and investments.
• The company increased its adjusted EBITDA outlook for fiscal year 2024.
• The company has secured a significant strategic agreement in the U.S. market.

Negatives

• The company reported a net loss of $3.3 million for the quarter, compared to a net income of $2.7 million in the same period last year.
• Adjusted EBITDA decreased to $5.3 million from $10.0 million in the prior year quarter.
• Operating expenses increased significantly, impacting profitability.
• The company experienced losses on foreign currency transactions.

Risks

• Global economic conditions could impact sales and profitability.
• Regulatory approvals for new or improved products could be delayed or denied.
• International conflicts and trade disputes could affect the company's operations.
• The company is substantially dependent on demand from Asia.
• The willingness of surgeons and patients to adopt new products and procedures is a risk.

Future Outlook

The company reiterates its net sales outlook for fiscal year 2024 to be between $335 million and $340 million and increased its adjusted EBITDA outlook to approximately $39 million, or $0.75 per diluted share.

Management Comments

• Our first quarter results illustrate the impact of our commercial focus, which is driving continued market adoption and share gains of our EVO ICL, said Tom Frinzi, President and CEO of STAAR Surgical.
• Our strategic investments in people and processes in recent quarters are now bearing fruit.
• We are very pleased by the quickening pace of our momentum to start 2024, marked by several significant business milestones, including todays announcement of the largest-ever practice commitment to EVO ICL in the U.S.
• In the first quarter, STAAR continued to capture market share during a challenging macroeconomic environment for our surgeon customers and their patients.
• We saw strong momentum and remain well positioned to capitalize on our growth opportunities.

Industry Context

The announcement highlights STAAR Surgical's continued growth in the refractive surgery market, particularly with its EVO ICL product, despite a challenging macroeconomic environment. The company's focus on strategic investments and commercial expansion appears to be yielding positive results, positioning it well against competitors in the ophthalmic surgery space.

Comparison to Industry Standards

• While specific competitor data is not provided in the document, STAAR's 9% ICL sales growth and 2% unit growth indicate a strong performance in the refractive surgery market, which is generally experiencing growth.
• The company's gross margin of 78.9% is relatively high, suggesting efficient operations and pricing power.
• The adjusted EBITDA of $5.3 million is lower than the previous year, indicating increased operating expenses, which is a concern.
• The company's cash position of $252.1 million is strong, providing financial flexibility for future growth and investments.
• The company's growth in specific regions such as the U.S. (15% year-over-year), China (10% year-over-year) and EMEA (11% year-over-year) is a positive sign, indicating a strong global presence.

Stakeholder Impact

• Shareholders may be concerned about the net loss and decreased adjusted EBITDA, but encouraged by the increased sales and positive outlook.
• Employees may be impacted by the company's performance and future growth plans.
• Customers (surgeons and patients) will benefit from the continued availability and improvement of the EVO ICL product.
• Suppliers may see increased demand for their products and services.
• Creditors will be interested in the company's financial stability and ability to meet its obligations.

Next Steps

• The company will host a conference call and webcast on May 7, 2024, to discuss the financial results and operational progress.
• The company will continue to focus on commercial expansion and strategic investments to drive future growth.

Key Dates

Keywords

EVO ICL, Implantable Collamer Lens, Refractive Surgery, Ophthalmology, Net Sales, Adjusted EBITDA, Gross Margin, Financial Results, APAC, EMEA, Americas